About Kesmalea
Kesmalea is a company based in London (United Kingdom) founded in 2020 by Harry Finch.. Kesmalea has raised $62.03 million across 4 funding rounds. Kesmalea offers products and services including SELFTAC Platform and Therapeutics Pipeline. Kesmalea operates in a competitive market with competitors including Nuclera Nucleics, Encodia, Tierra Biosciences, Amide Technologies and mk2 Biotechnologies, among others.
- Headquarter London, United Kingdom
- Founders Harry Finch
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$62.03 M (USD)
in 4 rounds
-
Latest Funding Round
$13.14 M (USD), Series B
Sep 03, 2024
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kesmalea
Kesmalea offers a comprehensive portfolio of products and services, including SELFTAC Platform and Therapeutics Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Converts large protein degraders into small molecules for disease treatment
Advances novel drugs for oncology and CNS via targeted degradation
Unlock access to complete
Funding Insights of Kesmalea
Kesmalea has successfully raised a total of $62.03M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $13.14 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $13.1M
-
First Round
First Round
(01 Jun 2022)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Series B - Kesmalea | Valuation |
investors |
|
| Sep, 2023 | Amount | Series B - Kesmalea | Valuation |
investors |
|
| Sep, 2022 | Amount | Series A - Kesmalea | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Kesmalea
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kesmalea
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kesmalea Comparisons
Competitors of Kesmalea
Kesmalea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, Encodia, Tierra Biosciences, Amide Technologies and mk2 Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Desktop bioprinter for genes and proteins production is developed.
|
|
| domain | founded_year | HQ Location |
Technology platforms for integrative proteomic analysis are developed.
|
|
| domain | founded_year | HQ Location |
AI-based tools for protein development and custom synthesis are offered.
|
|
| domain | founded_year | HQ Location |
Automated peptide synthesis platform is developed with precision reagents.
|
|
| domain | founded_year | HQ Location |
Peptides and proteins are developed for life science applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Kesmalea
When was Kesmalea founded?
Kesmalea was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Where is Kesmalea located?
Kesmalea is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Is Kesmalea a funded company?
Kesmalea is a funded company, having raised a total of $62.03M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5.75M, raised on Jun 01, 2022.
What does Kesmalea do?
Kesmalea was founded in 2020 and is based in London, United Kingdom. Operations are centered in the biotechnology sector, where novel protein degraders are discovered to maintain protein equilibrium in the human body. An intricate system is employed for the continuous synthesis and regulation of proteins, targeting therapeutic applications in healthcare.
Who are the top competitors of Kesmalea?
Kesmalea's top competitors include Nuclera Nucleics, Encodia and Tierra Biosciences.
What products or services does Kesmalea offer?
Kesmalea offers SELFTAC Platform and Therapeutics Pipeline.